Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Authors:
- Bach ArdalanBABach Ardalan
- Aaron CinerACAaron Ciner
- Yasmine BacaYBYasmine Baca
- Andrew HintonAHAndrew Hinton
- Sourat DarabiSourat Darabi
- Anup KasiAKAnup Kasi
- Emil LouELEmil Lou
- Jose Ignacio AzquetaJAJose Ignacio Azqueta
- Joanne XiuJXJoanne Xiu
- Jashodeep DattaJDJashodeep Datta
- Anthony F. ShieldsASAnthony F. Shields
- Andrew AguirreAAAndrew Aguirre
Top Cited Papers
Open Access
- 16 January 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (6) , 1082-1090
Abstract
Purpose: Oncogenic mutations in KRAS have been identified in >85% of pancreatic ductal adenocarcinoma (PDAC) cases, with G12D, G12V, and G12R being the most frequent variants. Using large clinical and genomic databases, this study characterizes prognostic and molecular differences between KRAS variants, focusing on KRASG12D and KRASG12R. Experimental Design: PDAC samples were tested using DNA and RNA sequencing. The MAPK activation score and tumor microenvironment were analyzed from RNA expression data. Real-world overall survival (OS) obtained from insurance claims data was calculated from tissue collection to last contact. Significance was determined by χ2 and Fisher exact tests. Results: A total of 3,755 patients with PDAC harboring KRASG12D (n = 1,766), KRASG12V (n = 1,294), KRASG12R (n = 621), or KRASG12C (n = 74) variants were identified. Patients with G12R mutations had longer OS compared with those with G12D overall (12.7 vs. 10.1 months; P value = 0.0001), with similar trends in patients treated with gemcitabine/nab-paclitaxel (13.5 vs. 10.4 months; P value = 0.0002) or FOLFIRINOX (18.3 vs. 14.0 months; P value<0.001). ARID1A and KMT2D mutations were more frequent in the G12D subgroup. Several genes involved in glucose and glutamine metabolism were less expressed in G12R compared with G12D. PD-L1 expression was lower in G12R compared with G12D (13% vs. 19%). Conclusions: KRAS G12D tumors exhibited a distinct molecular profile compared with G12R tumors, including genes involved in the MAPK pathway, immune activation, and glucose and glutamine metabolism. Patients with G12D mutations had lower OS compared with those with G12R. Based on these data, future studies should address the KRAS mutation status and explore distinct therapeutic vulnerabilities.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal AdenocarcinomaJAMA Oncology, 2018
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic CancerCold Spring Harbor Perspectives in Medicine, 2017
- Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanomaProceedings of the National Academy of Sciences, 2016
- Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expressionGenome Biology, 2016
- KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic AdenocarcinomaClinical and Translational Gastroenterology, 2016
- Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient SurvivalPLOS ONE, 2013
- Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient SurvivalPancreas, 2013
- Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancerJournal of Gastroenterology, 2012
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF-1, cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinomaInternational Journal of Cancer, 2000